UK Early Detection Initiative for Pancreatic Cancer
Type of opportunity:
Review of trial documents. There is also an opportunity for one individual to join the study steering committee as an independent member. This committee would meet 1-2 times per year (often via teleconference). As this programme has quite a wide remit there may be other opportunities that materialise for further input from lay representatives. This opportunity is open to anyone in the Research Involvement Network based in the UK.
Please get in touch by no later than Friday 11th October 2019.
Further info on Trial Steering Committees (TSC):
The Trial Steering Committee is a committee formed to provide overall independent supervision for the trial, it will consist of independent members with relevant scientific and medical expertise along with patient representation. The TSC will endeavour to ensure that the study is conducted in accordance with the required regulatory and scientific standards.
Typically the TSC will meet once or twice a year generally via teleconference, a typical meeting would last up to one hour. A report will be provided to the committee by the trial management group prior to the meeting detailing the progress and conduct of the study, e.g. recruitment rates, research sites open, data collection, deviations from the protocol etc. The report and any issues raised will be discussed and the TSC will make recommendations about the further conduct of the study. This can include decisions such as continuation or termination of the study, whether amendments or changes in study conduct are required and overall advising the trial management group on all aspects of the study.
About the study:
UK-EDI is a Cancer Research UK funded programme grant attempting to identify markers in patients in with new onset diabetes, a high risk group for developing pancreatic cancer, that will permit the identification of the subpopulation with the greatest probability of a diagnosis of pancreatic cancer.
At the time of diagnosis of pancreatic cancer, an estimated 65% of patients have diabetes mellitus (DM), rising to 80% including those with glucose intolerance. While approximately 15% of diabetes mellitus in pancreatic cancer patients is long-standing (present >3 years) the remainder is new-onset-diabetes mellitus. The latter often goes undiagnosed, and when it is diagnosed, in the majority of cases this comes within one year prior to the pancreatic cancer being identified. In effect, new-onset diabetes mellitus is an early warning sign of the presence of pancreatic cancer, and individuals with new-onset diabetes mellitus are a high-risk group for pancreatic cancer. Approximately 0.8-1% of individuals diagnosed with type 2 diabetes mellitus (T2DM) have (undiagnosed) pancreatic cancer. This group of individuals actually has pancreatic cancer associated DM, although it is mistakenly diagnosed as T2DM.
Currently, the scientific/medical community does not know how to respond to this problem and individuals with new-onset DM are not screened for pancreatic cancer. Developing methods for PDAC detection in individuals with new-onset DM will require relevant early-stage, pre-diagnostic samples and corresponding patient data.
Who is conducting the research?
The Chief Investigator is Professor Eithne Costello based at the University of Liverpool. The research will be managed by the Liverpool Clinical Trials Centre.
When will this trial be recruiting/taking place?
The UK-EDI programme intends to start recruiting participants before end 2019. We aim to recruit 2500 participants over approx. 3 years. The researchers aim to hold the first steering committee meeting in November 2019.
Who can take up this opportunity?
Anyone with experience of pancreatic cancer (patients, family, carers).
Who has reviewed the study?
The study has been reviewed by the NCRI pancreatic subgroup, Liverpool pancreatic patients group and Cancer Research UK.
How will the study benefit people affected by pancreatic cancer?
The ultimate aim of this study is to identify biomarkers that will enable a screening programme for high risk individuals to diagnose pancreatic cancer much earlier than is currently the case and therefore significantly improve the prognosis for these patients.
What next/who to contact:
Please contact the programme coordinator Mr Robert Hanson at the University of Liverpool with expressions of interest including a short summary of how you have been affected by pancreatic cancer. You can send him an email or call him on 0151 794 8852.